Fecal Microbiota(Helsinki University Central Hospital)(Fecal Microbiota(Helsinki University Central Hospital))

概要

基本信息

药物类型

粪菌移植

别名-

靶点-

作用机制

细菌替代物、微生物调节剂

治疗领域

感染泌尿生殖系统疾病

在研适应症

泌尿道感染

非在研适应症-

原研机构

Helsinki University Central Hospital

在研机构

Helsinki University Central Hospital

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Fecal Microbiota(Helsinki University Central Hospital) 相关的临床试验

NCT06227845 / Not yet recruitingN/AIIT

Preterm Infant Intestinal Microbiota Development and Maternal Fecal Transplant

The goal of this clinical trial is to study if a oral maternal fecal transplant given to a premature infant born by cesarean section (CS) is safe. The investigators will also compare the gut microbiome of the infants to those born by CS and not received the transplant and to premature infants born vaginally.

开始日期2024-02-01

申办/合作机构

Helsinki University Central Hospital

[+2]

NCT06050148 / Recruiting临床2/3期IIT

Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections

This study investigates Faecal microbiota transplantation (FMT) in prevention of recurrent urinary tract infections (UTIs) caused either by sensitive E. coli or ESBL-E. coli.

开始日期2023-08-01

申办/合作机构

Helsinki University Central Hospital

[+1]

100 项与 Fecal Microbiota(Helsinki University Central Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Fecal Microbiota(Helsinki University Central Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Fecal Microbiota(Helsinki University Central Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 Fecal Microbiota(Helsinki University Central Hospital) 相关的药物交易

登录后查看更多信息